EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische Studie

Association Between Daily Timing of Everolimus and Survival in High‐Risk HR +/ HER2 − Early Breast Cancer: A Sub‐Analysis of the UCBG‐UNIRAD Trial

Enora Laas iD, Anne-Sophie Hamy, Thomas Bachelot, Paul Gougis iD, Jérôme Lemonnier iD, Fabrice André, David Cameron, Judith Bliss, Sylvie Chabaud iD, Anne-Claire Hardy-Bessard iD, Magali Lacroix-Triki, Djelila Allouache und 13 weitere

Clinical Pharmacology & Therapeutics · 2025

DOI: 10.1002/cpt.70030 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology & Therapeutics, 2025. Verfasst von Enora Laas und 24 weiteren Autor:innen. Beteiligte Einrichtung: Residual Tumor and Response to Treatment, U932 Immunity and Cancer, Institut Curie, Paris, France. Hauptthemen laut MEDLINE: Everolimus, Breast Neoplasms, Antineoplastic Agents. Die Arbeit nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the UNIRAD phase III trial, evening intake of tamoxifen was previously associated with improved disease‐free survival (DFS), while no timing effect was observed for aromatase inhibitors. This sub‐study evaluated whether the timing of everolimus intake affects DFS in patients receiving adjuvant endocrine therapy (ET). A total of 1278 patients with high‐risk HR+/HER2− early breast cancer were randomized to receive adjuvant ET with either placebo or everolimus. Patients prospectively recorded the timing of both ET and everolimus intake using four time slots: morning (06:00–11:59), afternoon (12:00–17:59), evening (18:00–23:59), and night (00:00–05:59). The relationship between intake timing and DFS was a pre‐specified secondary endpoint. Timing data were available for 513 of 632 patients (81.2%) in the everolimus arm. After a median follow‐up of 60.6 months, 15 local relapses, 55 metastases, and 36 deaths were reported. Overall, everolimus timing had no significant association with DFS (HR = 0.84, 95% CI 0.53–1.35, P = 0.4). However, a significant interaction was found between everolimus timing and ET type ( P = 0.001). Among tamoxifen users, evening/night intake of everolimus significantly improved DFS compared to morning/afternoon intake (HR = 0.17, 95% CI 0.05–0.59, P = 0.005), independently of tamoxifen timing. No timing effect was observed in patients on aromatase inhibitors (HR = 1.56, P = 0.1). In multivariate analysis, evening/night everolimus with tamoxifen remained an independent predictor of improved DFS (HR = 0.13, P = 0.002). Evening or nighttime intake of everolimus may enhance the efficacy of tamoxifen‐based adjuvant therapy in high‐risk HR+/HER2− early breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EverolimusBreast NeoplasmsAntineoplastic AgentsHumansFemaleMiddle AgedTamoxifenDisease-Free SurvivalAdultErb-b2 Receptor Tyrosine KinasesAgedChemotherapy, AdjuvantTime FactorsReceptors, EstrogenAntineoplastic Agents, HormonalTreatment Outcome

Substanzen

EverolimusTamoxifenErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenAntineoplastic Agents, HormonalAntineoplastic AgentsERBB2 protein, human

Autor:innen und Institutionen

  • Residual Tumor and Response to Treatment, U932 Immunity and Cancer, Institut Curie, Paris, France.
  • Surgery Department, Institut Curie, Universite Paris Cite, Paris, France.
  • Medical Oncology, Institut Curie, Universite Paris Cité, Paris, France.
  • Medical Oncology, Centre Leon Berard, Lyon, France.
  • R&D Unicancer, Paris, France.
  • Gustave Roussy, Villejuif, France.

ORCID-Profile: Enora Laas, Paul Gougis, Jérôme Lemonnier, Sylvie Chabaud, Anne-Claire Hardy-Bessard, Frédérique Penault-Llorca, Francis Lévi, Sylvie Giacchetti

Zitieren

APA

Laas, E., Hamy, A. S., Bachelot, T., Gougis, P., Lemonnier, J., André, F., Cameron, D., Bliss, J., Chabaud, S., Hardy-Bessard, A. C., Lacroix-Triki, M., Allouache, D., Debled, M., Campone, M., Venat-Bouvet, L., Cottu, P., Martinez, M., Grenier, J., Dalenc, F., …, & Giacchetti, S. (2025). Association Between Daily Timing of Everolimus and Survival in High‐Risk HR +/ HER2 − Early Breast Cancer: A Sub‐Analysis of the UCBG‐UNIRAD Trial. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70030

Vancouver

Laas E, Hamy AS, Bachelot T, Gougis P, Lemonnier J, André F, et al. Association Between Daily Timing of Everolimus and Survival in High‐Risk HR +/ HER2 − Early Breast Cancer: A Sub‐Analysis of the UCBG‐UNIRAD Trial. Clinical Pharmacology & Therapeutics. 2025. doi:10.1002/cpt.70030

BibTeX
@article{Laas2025,
  author = {Laas, Enora and Hamy, Anne-Sophie and Bachelot, Thomas and Gougis, Paul and Lemonnier, Jérôme and André, Fabrice and Cameron, David and Bliss, Judith and Chabaud, Sylvie and Hardy-Bessard, Anne-Claire and Lacroix-Triki, Magali and Allouache, Djelila and Debled, Marc and Campone, Mario and Venat-Bouvet, Laurence and Cottu, Paul and Martinez, Mathilde and Grenier, Julien and Dalenc, Florence and Dumas, Elise and Reyal, Fabien and Asselain, Bernard and Penault-Llorca, Frédérique and Lévi, Francis and Giacchetti, Sylvie},
  title = {Association Between Daily Timing of Everolimus and Survival in High‐Risk HR +/ HER2 − Early Breast Cancer: A Sub‐Analysis of the UCBG‐UNIRAD Trial},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1002/cpt.70030}
}
Kostenlos starten →